Listen to the Latest ‘KFF Health News Minute’
kffhealthnews - The "KFF Health News Minute" brings original health care and health policy reporting from our newsroom to the airwaves each week.
AI Summary: A phase 2 study investigated FGFR inhibition with rogaratinib in succinate dehydrogenase–deficient gastrointestinal stromal tumors. Results reported tumor control in this rare molecular subset, offering a targeted therapeutic approach where options are sparse and validating FGFR as a biologic vulnerability in SDH‑deficient GIST.
Related Stories
Enhertu (DESTINY‑Lung04) improves PFS in HER2‑mutant lung cancer / 6 days
Engineered bacteria show promise as tumor‑targeting therapy in preclinical studies / 5 wks
Daraxonrasib shows encouraging activity in NRAS-driven melanoma patients / 6 wks
Genetic clues explain tagraxofusp resistance in rare leukemia (BPDCN) / 7 wks
Adjuvant selpercatinib sharply cuts recurrence in RET‑fusion lung cancer / 2 months
CRISPR CD33‑deleted allogeneic transplant shows early AML promise / 3 months
Single‑cycle pembrolizumab yields striking responses in dMMR colon cancer / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Mergers and Acquisitions, Hearing Loss, Telemedicine, Clinical Trials and look for the RSS link.
StackHealth Time Machine